Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
Van Laethem, Jean-Luc, Riess, Hanno, Jassem, Jacek, Haas, Michael, Martens, Uwe M., Weekes, Colin, Peeters, Marc, Ross, Paul, Bridgewater, John, Melichar, Bohuslav, Cascinu, Stefano, Saramak, Piotr, Michl, Patrick, Van Brummelen, David, Zaniboni, Alberto, Schmiegel, Wollf, Dueland, Svein, Giurescu, Marius, Garosi, Vittorio L., Roth, Katrin, Schulz, Anke, Seidel, Henrik, Rajagopalan, Prabhu, Teufel, Michael, Childs, Barrett H.
Published in Targeted oncology (01.02.2017)
Published in Targeted oncology (01.02.2017)
Get full text
Journal Article
Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results
Riess, Hanno, Van Laethem, Jean-Luc, Martens, Uwe Marc, Heinemann, Volker, Michl, Patrick, Peeters, Marc, Van Brummelen, David, Weekes, Colin D., Dueland, Svein, Schmiegel, Wolff H., Giurescu, Marius, Garosi, Vittorio Luigi, Schulz, Anke, Seidel, Henrik, Childs, Barrett H., Teufel, Michael
Published in Journal of clinical oncology (20.05.2014)
Published in Journal of clinical oncology (20.05.2014)
Get full text
Journal Article